Guyatt Gordon H, Cranney Ann, Griffith Lauren, Walter Stephen, Krolicki Nicole, Favus Murray, Rosen Clifford
Department of Medicine, Department of Clinical Epidemiology and Biostatistics, McMaster University, 1200 Main Street West, Hamilton, Ontario, Canada, L8N 3Z5.
Endocrinol Metab Clin North Am. 2002 Sep;31(3):659-79, xii. doi: 10.1016/s0889-8529(02)00024-5.
We review the methodologic quality of the individual randomized trials and summarize the impact of different treatments on the risk of fractures and bone density. We present an estimate of the expected impact of anti-osteoporosis interventions on fracture incidence in prevention and treatment populations using numbers needed to treat. We also examine the relationship between changes in bone density and the relative risk reduction for vertebral and nonvertebral fractures using regression analyses drawn from the results of the systematic reviews. We also outline other important facets of the decision-making process regarding osteoporosis therapy, including attitudes toward uncertainty, circumstances, and patients' and societal preferences.
我们回顾了各个随机试验的方法学质量,并总结了不同治疗方法对骨折风险和骨密度的影响。我们使用需治疗人数来估计抗骨质疏松干预措施对预防和治疗人群骨折发生率的预期影响。我们还通过系统评价结果进行回归分析,研究骨密度变化与椎体和非椎体骨折相对风险降低之间的关系。我们还概述了骨质疏松症治疗决策过程的其他重要方面,包括对不确定性的态度、具体情况以及患者和社会的偏好。